Advertisement

Topics

Eosinophilic Esophagitis - Pipeline Review, H1 2015

05:01 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Eosinophilic Esophagitis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 67-page report is available in PDF from $2000.

Eosinophilic Esophagitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Eosinophilic Esophagitis - Pipeline Review, H1 2015’, provides an overview of the Eosinophilic Esophagitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eosinophilic Esophagitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Eosinophilic Esophagitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Eosinophilic Esophagitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Eosinophilic Esophagitis Overview 7
Therapeutics Development 8
Pipeline Products for Eosinophilic Esophagitis - Overview 8
Pipeline Products for Eosinophilic Esophagitis - Comparative Analysis 9
Eosinophilic Esophagitis - Therapeutics under Development by Companies 10
Eosinophilic Esophagitis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Eosinophilic Esophagitis - Products under Development by Companies 14
Eosinophilic Esophagitis - Companies Involved in Therapeutics Development 15
Actavis plc 15
DBV Technologies S.A. 16
Dr. Falk Pharma GmbH 17
Lipella Pharmaceuticals, Inc. 18
Novartis AG 19
Oxagen Limited 20
Receptos, Inc. 21
Regeneron Pharmaceuticals, Inc. 22
Shire Plc 23
Teva Pharmaceutical Industries Limited 24
Eosinophilic Esophagitis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
Allergen for Milk Allergy - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
budesonide - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
budesonide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dupilumab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EUR-1100 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
OC-459 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
QAX-576 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
reslizumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
RPC-4046 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
tacrolimus liposomal - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Eosinophilic Esophagitis - Recent Pipeline Updates 50
Eosinophilic Esophagitis - Dormant Projects 58
Eosinophilic Esophagitis - Product Development Milestones 59
Featured News & Press Releases 59
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 59
Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients 59
Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis 60
May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children 61
Aug…

For more information open Eosinophilic Esophagitis - Pipeline Review, H1 2015.

SKU: GMDHC6633IDB

Original Article: Eosinophilic Esophagitis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Eosinophilic Esophagitis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...